Bezlotoxumab
Top View
- GUIDANCE on the USE of INTERNATIONAL NONPROPRIETARY NAMES (Inns) for PHARMACEUTICAL SUBSTANCES
- Estonian Statistics on Medicines 2017 1/42
- Zinplava™ (Bezlotoxumab) Medical Policy
- ATC-Code J06: Immunsera Und Im- Munglobuline
- Development and Challenges to Monoclonal Antibodies for Passive Immunization
- AMB PARENTERALE AB THERAPIE Bilder, Hinweise & Interessenskonflikte AMB PARENTERALE AB THERAPIE Planungsalgorithmus
- Expanding Access to Monoclonal Antibody-Based Products
- Efficacy of Bezlotoxumab, the Monoclonal Antibody Targeting C. Difficile Toxin B, for Prevention of C. Difficile Infection
- ZINPLAVA Safely and Effectively
- Preventing and Treating Recurrent Clostridioides Difficile Infection in High‐Risk Populations: a Pro/Con Debate
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- 2016 NOVEL DRUGS Summary
- Alphabetical Listing by Name Dod UNIFORM OUTPATIENT
- Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
- Antibiotics in the Clinical Pipeline in October 2019
- Bezlotoxumab for Prevention of Recurrent C. Difficile Infection in High-Risk Patients
- ZINPLAVA, INN-Bezlotoxumab
- COMMISSION DE LA TRANSPARENCE Avis 19 Juillet 2017